Gitte‐Bettina Nyvang

From point A to the sculpted pear: MR image guidance significantly improves tumour dose and sparing of organs at risk in brachytherapy of cervical cancer

Kari Tanderup, S.K. Nielsen, Gitte‐Bettina Nyvang et al. · Radiotherapy and Oncology · 2010 · 213 citations

Cervical Cancer, Medical Imaging, Radiation Therapy +10

Durvalumab with paclitaxel/carboplatin (PC) and bevacizumab (bev), followed by maintenance durvalumab, bev, and olaparib in patients (pts) with newly diagnosed advanced ovarian cancer (AOC) without a tumor BRCA1/2 mutation (non-tBRCAm): Results from the randomized, placebo (pbo)-controlled phase III DUO-O trial.

Philipp Harter, Fabian Trillsch, Aikou Okamoto et al. · Journal of Clinical Oncology · 2023 · 50 citations

Surgical Oncology, Immunology, Immunoediting +21

DUO-O: A randomized phase III trial of durvalumab (durva) in combination with chemotherapy and bevacizumab (bev), followed by maintenance durva, bev and olaparib (olap), in newly diagnosed advanced ovarian cancer patients.

Philipp Harter, Mariusz Bidziński, Nicoletta Colombo et al. · Journal of Clinical Oncology · 2019 · 46 citations

Surgical Oncology, Tps5598 Background, Cancer Management +18

The Diagnostic Value of Circulating Cell-Free HPV DNA in Plasma from Cervical Cancer Patients

Sara Bønløkke, Magnus Stougaard, Boe Sandahl Sørensen et al. · Cells · 2022 · 33 citations · Full text

Trends in gynecologic cancer among elderly women in Denmark, 1980–2012

Anja Ør Knudsen, Doris Schledermann, Gitte‐Bettina Nyvang et al. · Acta Oncologica · 2016 · 28 citations · Full text